Article
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
The Journal of clinical investigation - 1 Jul 2014
Anastas Jamie N, Kulikauskas Rima M, Tamir Tigist, Rizos Helen, Long Georgina V, von Euw Erika M, Yang Pei-Tzu, Chen Hsiao-Wang, Haydu Lauren, Toroni Rachel A, Lucero Olivia M, Chien Andy J, Moon Randall T
Abstract excerpt
About half of all melanomas harbor a mutation that results in a constitutively active BRAF kinase mutant (BRAF(V600E/K)) that can be selectively inhibited by targeted BRAF inhibitors (BRAFis). While patients treated with BRAFis initially exhibit measurable clinical improvement, the majority of patients eventually develop drug resistance and relapse. Here, we observed marked elevation of WNT5A in a subset of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.